Literature DB >> 10769671

Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas.

H C Ludwig1, I Feiz-Erfan, V Bockermann, J Behnke-Mursch, K Schallock, E Markakis.   

Abstract

BACKGROUND: Nitric oxide (NO) is synthesized from arginine by three different isozymes of nitric oxide synthase (NOS I-III). NO has been identified as a powerful metabolite of vascular smooth muscle cell function, cerebral blood circulation and oedema induction. NOS induction by different cytokines has been shown previously in glioblastoma cell cultures and NOS III expression due to astrocytoma grading has been shown in several tumors recently. The aim of the present study was to study the coexpression of NOS I-III, macrophage and capillary presence with VEGF, EGF and their receptors and to investigate a possible mechanism in peritumoral oedema generation.
MATERIALS AND METHODS: We have investigated the expression (4-grade values, blinded assay by two observers) of NOS I-III together with those of VEGF, VEGF- R (Flt-1), EGF-R1, von-Willebrand-factor (VWF) and a pan-macrophage marker (Ki-M1P) immunohistochemically in tumor specimens from 220 patients and performed tumor volume morphometry by image analysis in a subgroup of 32 cases to test for any correlation with the peritumoral oedema volumes. Inducible NOS II was further investigated by in situ labelling with a DNA oligonucleotide probe cocktail.
RESULTS: All of the specimens revealed some NOS expression, NOS II was expressed in macrophages, microglia and endothelial cells, NOS III and I was localized in glioblastoma cells, NOS III in endothelial cells as well. The highest degrees of expression were observed in 46% (NOS I), 22% (NOS II) and 75% (NOS III) of all specimens. Inducible NOS II in any expression grade was observed in 47.5% of the specimens. Significant correlations were observed for the expression of the macrophage marker Ki-M1P with NOS II (p = 0.024), endothelial NOS III with NOS I (p = 0.0003), VEGF-R1 with NOS II (p = 0.0008) and NOS III (p = 0.011) The oedema volumes could not be correlated significantly with NOS or VEGF-R1 expression values but with those of endothelial staining (p = 0.02). We observed a trend towards higher Ki-M1P expression values together with higher oedema volume extensions. In situ hybridization demonstrated reaction products in endothelial and perivascular regions and sometimes scattered throughout the specimens revealing the labelling of macrophages.
CONCLUSIONS: The main source of NO is NOS I and NOS III. The latter is located in endothelial cells and glioblastoma cells. The expression of NOS II in glioblastomas is restricted to infiltrating macrophages. NOS II and III expressions were observed significantly together with that of VEGF-R1. Neither NOS I-III nor VEGF-R expression could be correlated with the extension of the peritumoral oedema.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769671

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  NOS Expression and NO Function in Glioma and Implications for Patient Therapies.

Authors:  Anh N Tran; Nathaniel H Boyd; Kiera Walker; Anita B Hjelmeland
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

2.  Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma.

Authors:  Jian-Wei Pan; Ren-ya Zhan; Ying Tong; Yong-qing Zhou; Ming Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

3.  Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide.

Authors:  Nicholas A Pullen; Helen L Fillmore
Journal:  J Neurooncol       Date:  2009-07-21       Impact factor: 4.130

4.  Elevated nitric oxide levels in childhood brain tumors.

Authors:  Chung-Lan Kao; Shih-Hwa Chiou; Hong-Shin Chen; Donald Ming-Tak Ho; Chieh-Fu Chen; Larry L-T Ho; Meng-Jer Lee; Tai-Tong Wong
Journal:  Childs Nerv Syst       Date:  2003-09-11       Impact factor: 1.475

5.  MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication.

Authors:  J Zhou; M V Reddy; B K J Wilson; D A Blair; A Taha; C M Frampton; R A Eiholzer; P Y C Gan; F Ziad; Z Thotathil; S Kirs; N A Hung; J A Royds; T L Slatter
Journal:  AJNR Am J Neuroradiol       Date:  2017-11-30       Impact factor: 3.825

6.  Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.

Authors:  Noelyn A Hung; Ramona A Eiholzer; Stenar Kirs; Jean Zhou; Kirsten Ward-Hartstonge; Anna K Wiles; Chris M Frampton; Ahmad Taha; Janice A Royds; Tania L Slatter
Journal:  Mod Pathol       Date:  2016-01-15       Impact factor: 7.842

7.  Influence of caloric restriction on constitutive expression of NF-κB in an experimental mouse astrocytoma.

Authors:  Tiernan J Mulrooney; Jeremy Marsh; Ivan Urits; Thomas N Seyfried; Purna Mukherjee
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

8.  Reciprocal Supportive Interplay between Glioblastoma and Tumor-Associated Macrophages.

Authors:  Wenchao Zhou; Shideng Bao
Journal:  Cancers (Basel)       Date:  2014-03-26       Impact factor: 6.639

9.  Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.

Authors:  Wenchao Zhou; Susan Q Ke; Zhi Huang; William Flavahan; Xiaoguang Fang; Jeremy Paul; Ling Wu; Andrew E Sloan; Roger E McLendon; Xiaoxia Li; Jeremy N Rich; Shideng Bao
Journal:  Nat Cell Biol       Date:  2015-01-12       Impact factor: 28.824

Review 10.  Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.

Authors:  Ivy A W Ho; Winston S N Shim
Journal:  Biomed Res Int       Date:  2017-05-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.